CurrentHealth-New-EnglandPolicy N/A

Pharmacy Benefit — HMO Silver 2000 HDHP SG: Copay Tiers and Prior Authorization for Brand-Name Drugs

Defines retail and mail-order copay amounts, explains copay tier definitions, and describes prior authorization/medical necessity requirements for brand-name drugs with FDA-approved generics for members of the HMO Silver 2000 HDHP SG plan.

Policy Summary

PayerHealth-New-England

PolicyPharmacy Benefit — HMO Silver 2000 HDHP SG: Copay Tiers and Prior Authorization for Brand-Name Drugs

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit a drug request form and fax documentation demonstrating medical necessity to request prior authorization for a brand-name drug when an FDA-approved generic exists.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

$30/$60/$105Retail copays (G / BF / BNF)

$60/$120/$315Mail-order copays (G / BF / BNF)

Combined med/pharmacyDeductible

MassachusettsState rule

Coverage criteria for brand-name drugs with FDA-approved generics

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage of Brand Name Drugs with FDA-Approved Generics

Covered when ALL of the following are met

Brand with generic requires medical necessity: Brand name drug has an FDA-approved generic equivalent AND medical necessity is documented

Medical necessity examples include inadequate response or allergic reaction to the generic(s) and failure of alternatives in the drug class.

Brand name drugs that have FDA-approved generic equivalents are not covered without demonstrated medical necessity. Health New England covers these brand-name products only when documentation shows that medical necessity exists (for example, inadequate response or allergic reaction to the generic, or failure of alternatives in the drug class).

The use of a brand-name drug when an FDA-approved generic equivalent is available is considered not medically necessary for coverage purposes unless the provider submits documentation demonstrating medical necessity. Providers may request prior authorization by completing a drug request form and faxing supporting documentation to Health New England for review.

Provider actions, prior authorization, and documentation requirements

Prior Authorization

Prior authorization required for brand-name drugs

Prior authorization is required for brand-name drugs that have FDA‑approved generic equivalents unless medical necessity is demonstrated. Providers should obtain prior authorization before dispensing or billing for these brand-name medications.

Brand name drugs with FDA‑approved generics require prior authorization unless medical necessity is shown.

Step Therapy

Implied step therapy expectations

Examples of clinical situations that may demonstrate medical necessity include, but are not limited to, inadequate clinical response to one or more FDA‑approved generic alternatives, allergic reaction or intolerance to the generic(s), or documented failure of other appropriate alternatives in the same therapeutic class.

Inadequate response to generic(s).
Allergic reaction or intolerance to generic(s).
Failure of alternatives in the drug class.

Documentation Required

Required documentation for brand-name drug requests

When requesting coverage of a brand-name drug that has an FDA‑approved generic equivalent, the provider must submit a completed drug request form and fax supporting clinical documentation that demonstrates medical necessity. Documentation may include clinical notes, prior treatment history, allergy documentation, lab results, and any other relevant records that justify use of the brand product.

Submit a completed drug request form.
Fax clinical documentation demonstrating medical necessity (e.g., treatment history, allergies, lab results).
Include details of prior trials and reasons for failure or intolerance to generics.

Denial Risk

Prior authorization/medical necessity risk for brand-name drugs

Brand-name drugs with available FDA‑approved generics will be denied if medical necessity is not documented. Lack of the required drug request form or supporting clinical evidence is a common reason for denial or delayed coverage.

Coverage denied if medical necessity is not demonstrated.
Incomplete requests (missing form or supporting documentation) risk denial or delay.

Formulary tier definitions

Generic / Tier 1

DefinitionFDA‑approved generics with the same active ingredients as the brand-name product; considered safe and effective alternatives and usually cost less.

Massachusetts dispensing rulePharmacists in Massachusetts are required to dispense the generic unless the prescriber writes 'no substitution' on the prescription.

Formulary tierTier 1 (Generic)

Brand Formulary / Tier 2

DefinitionBrand/Formulary drugs marketed under a trademarked brand name that do not have less expensive generic equivalents; selected for coverage based on relative safety, effectiveness, and cost.

Copay impactCopayment for Brand/Formulary drugs is higher than generic (Tier 1) but lower than Brand/Non‑Formulary (Tier 3).

Formulary tierTier 2 (Brand Formulary)

Brand Non-Formulary / Tier 3

DefinitionBrand name drugs that are not on the formulary (i.e., not Brand/Formulary); covered but at the highest copay level.

Coverage condition for brands with genericsBrand name drugs that have FDA‑approved generic equivalents are covered only if medical necessity is demonstrated (prior authorization may be required).

Formulary tierTier 3 (Brand Non‑Formulary)

Step therapy and required failure/intolerance documentation

Requirement	Details
Provider documentation requirement	Provider must document failure or intolerance to FDA‑approved generic(s) or failure of alternatives in the drug class to demonstrate medical necessity for a brand‑name drug that has an FDA‑approved generic equivalent.
Prior authorization process	Doctor may request prior authorization by completing a drug request form and faxing it to Health New England with supporting documentation of medical necessity (e.g., inadequate response or allergic reaction to generics, or failure of class alternatives).
Coverage consequence	Brand‑name drugs with FDA‑approved generic equivalents are covered only when medical necessity is shown; use without documentation is considered not medically necessary and may be denied.

Background and policy rationale

Generic drugs contain the same active ingredients as brand-name drugs and are considered safe and effective alternatives that usually cost less. In Massachusetts, pharmacists are required to dispense the generic product unless the prescriber indicates 'no substitution' on the prescription. For brand-name drugs that do have FDA-approved generics, coverage requires demonstration of medical necessity such as inadequate response or allergic reaction to the generic(s) or failure of alternatives in the drug class.